Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells

Kazuaki Taguchi, Toru Maruyama, Masaki Otagiri

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.

Original languageEnglish
Pages (from-to)362-373
Number of pages12
JournalDrug Metabolism Reviews
Volume43
Issue number3
DOIs
Publication statusPublished - 2011 Aug 1
Externally publishedYes

Fingerprint

Hemoglobins
Pharmacokinetics
Erythrocytes
Oxygen
Blood Safety
Fluorocarbons
Blood Volume
Blood Transfusion
Pharmacology
Costs and Cost Analysis
Research

Keywords

  • Accelerated blood clearance phenomenon
  • Artificial oxygen carrier
  • Disposition
  • Hemorrhagic shock
  • Hepatic chronic cirrhosis
  • Liposome
  • Mononuclear phagocyte system

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells. / Taguchi, Kazuaki; Maruyama, Toru; Otagiri, Masaki.

In: Drug Metabolism Reviews, Vol. 43, No. 3, 01.08.2011, p. 362-373.

Research output: Contribution to journalReview article

Taguchi, Kazuaki ; Maruyama, Toru ; Otagiri, Masaki. / Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells. In: Drug Metabolism Reviews. 2011 ; Vol. 43, No. 3. pp. 362-373.
@article{b8f7515785974c4f95ba4d3f8b5cd2c3,
title = "Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells",
abstract = "The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.",
keywords = "Accelerated blood clearance phenomenon, Artificial oxygen carrier, Disposition, Hemorrhagic shock, Hepatic chronic cirrhosis, Liposome, Mononuclear phagocyte system",
author = "Kazuaki Taguchi and Toru Maruyama and Masaki Otagiri",
year = "2011",
month = "8",
day = "1",
doi = "10.3109/03602532.2011.558094",
language = "English",
volume = "43",
pages = "362--373",
journal = "Drug Metabolism Reviews",
issn = "0360-2532",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells

AU - Taguchi, Kazuaki

AU - Maruyama, Toru

AU - Otagiri, Masaki

PY - 2011/8/1

Y1 - 2011/8/1

N2 - The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.

AB - The development of artificial oxygen carriers has attracted considerable recent interest because of the increasing cost of collecting and processing blood, public concerns about the safety of blood products, complications from blood transfusions, military requirements for increased volumes of blood during military conflicts, and a decrease in the number of new donors. To overcome these problems, perfluorocarbon-based oxygen carriers as well as acellular-and cellular-type, hemoglobin-based oxygen carriers have been developed for use as artificial oxygen carriers. Despite their extensive evaluation, including formulation and pharmacology, they have not been extensively used in clinical settings. One of the reasons for this is that their pharmacokinetics have not been well characterized. Artificial oxygen carriers require not only an acceptable level of physicochemical activity, but also clinical efficacy, as reflected by their retention in the circulation, and the absence of measurable accumulation in the body, if unexpected adverse effects are to be avoided. In this review, the pharmacokinetic properties of artificial oxygen carriers are discussed, with a focus on recent developments of our research related to the pharmacokinetic properties a cellular type of hemoglobin-based oxygen carrier.

KW - Accelerated blood clearance phenomenon

KW - Artificial oxygen carrier

KW - Disposition

KW - Hemorrhagic shock

KW - Hepatic chronic cirrhosis

KW - Liposome

KW - Mononuclear phagocyte system

UR - http://www.scopus.com/inward/record.url?scp=79960738078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960738078&partnerID=8YFLogxK

U2 - 10.3109/03602532.2011.558094

DO - 10.3109/03602532.2011.558094

M3 - Review article

VL - 43

SP - 362

EP - 373

JO - Drug Metabolism Reviews

JF - Drug Metabolism Reviews

SN - 0360-2532

IS - 3

ER -